Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation

Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation.


Extended antiviral healing after a lung uproot may hand curb treacherous complications and organ rejection, a strange study from Duke University Medical Center shows. A average cause of infection in lung resettle recipients is cytomegalovirus (CMV), which often causes quiet effects but can be life-threatening for remove patients. Standard preventive therapy involves prepossessing the drug valganciclovir (Valcyte) for up to three months pyridium bd. But even with this treatment, most lung shift patients demonstrate CMV infections within a year.



The Duke bookwork included 136 patients who completed three months of articulated valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of vocalized valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 manifold centers (one association of which received the additional medication and a mechanism bring that received the placebo, with neither the researchers nor the participants intelligent who was in the charge group) mens health supplements. Researchers found that CMV infection occurred in 10 percent of the extended care group, compared to 64 percent of the placebo group.